- Home
- RNA
as 11-14-2024 3:36pm EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 5.5B | IPO Year: | 2020 |
| Target Price: | $63.22 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.68 - $56.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | $10,117,000 | Revenue Growth: | -0.19% |
| Revenue Growth (this year): | 19.85% | Revenue Growth (next year): | -10.49% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MacLean Michael F | RNA | Chief Financial Officer | Nov 6 '24 | Sell | $45.63 | 106,319 | $4,843,979.06 | 94,093 | |
| LEVIN ARTHUR A | RNA | Director | Oct 21 '24 | Sell | $46.63 | 5,000 | $233,167.50 | 14,830 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Oct 16 '24 | Sell | $48.52 | 25,000 | $1,213,010.00 | 94,018 | |
| Thompson Tamar | RNA | Director | Oct 7 '24 | Sell | $44.98 | 30,000 | $1,349,259.00 | 0 | |
| Flanagan W. Michael | RNA | CSTO | Oct 1 '24 | Sell | $47.62 | 62,500 | $2,976,112.50 | 85,389 | |
| Boyce Sarah | RNA | President and CEO | Sep 19 '24 | Sell | $44.00 | 32,880 | $1,446,723.29 | 234,663 | |
| LEVIN ARTHUR A | RNA | Director | Sep 19 '24 | Sell | $45.73 | 5,000 | $228,658.00 | 14,830 | |
| MacLean Michael F | RNA | Chief Financial Officer | Sep 19 '24 | Sell | $44.00 | 11,510 | $506,440.00 | 94,093 | |
| Flanagan W. Michael | RNA | CSTO | Sep 19 '24 | Sell | $43.95 | 25,000 | $1,098,732.89 | 85,389 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Sep 19 '24 | Sell | $44.00 | 13,153 | $578,737.26 | 94,018 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
Zacks
19 hours ago
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Zacks
a day ago
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Investor's Business Daily
2 days ago
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
PR Newswire
3 days ago
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Simply Wall St.
6 days ago
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
8 days ago
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
PR Newswire
8 days ago
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
Zacks
9 days ago
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.